表柔比星、环磷酰胺联合白蛋白紫杉醇在乳腺癌患者中的应用效果  

Application Effect of Epirubicin,Cyclophosphamide Combined with Albumin-bound Paclitaxel in Patients with Breast Cancer

作　　者：陈建[1] 雷雯 林庆中[1] 黎世雄 CHEN Jian;LEI Wen;LIN Qingzhong;LI Shixiong(School of Clinical Oncology,Fujian Medical University,Fuzhou 350014,China)

机构地区：[1]福建医科大学肿瘤临床医学院(福建省肿瘤医院),福建福州350014

出　　处：《中外医学研究》2023年第30期5-9,共5页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探究表柔比星、环磷酰胺联合白蛋白紫杉醇在乳腺癌患者中的应用效果。方法:选择2021年6月—2022年9月福建医科大学肿瘤临床医学院收治的80例乳腺癌患者作为研究对象,根据随机数表法将患者分为对照组40例和观察组40例。对照组采用表柔比星、环磷酰胺联合多西他赛进行治疗,观察组采用表柔比星、环磷酰胺联合白蛋白紫杉醇进行治疗。比较两组治疗效果、各类毒副反应发生情况、治疗前后趋化因子相关指标[趋化因子配体5(CCL5)、趋化因子配体18(CCL18)及趋化因子配体20(CCL20)]及血管内皮生长因子(VEGF)亚型(VEGF-A、VEGF-B及VEGF-C)。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。两组各类毒副反应发生率比较,差异无统计学意义(P>0.05)。两组治疗前趋化因子相关指标及VEGF亚型比较,差异无统计学意义(P>0.05);观察组治疗2个周期、4个周期趋化因子相关指标及VEGF亚型均低于对照组,差异有统计学意义(P<0.05)。结论:表柔比星、环磷酰胺联合白蛋白紫杉醇在乳腺癌患者中的应用效果较好,安全性值得肯定,且可显著改善趋化因子相关指标及其对血管生成的影响。Objective:To investigate the application effect of Epirubicin,Cyclophosphamide combined with Albumin-bound Paclitaxel in patients with breast cancer.Method:A total of 80 patients with breast cancer who admitted to School of Clinical Oncology,Fujian Medical University from June 2021 to September 2022 were selected as the research objects,the patients were divided into the control group 40 cases and the observation group 40 cases according to the random number table method.The control group was treated with Epirubicin,Cyclophosphamide combined with Docetaxel,the observation group was treated with Epirubicin,Cyclophosphamide combined with Albumin-bound Paclitaxel.Then the treatment effect,various toxic and side effects rates,chemokine related indexes[CC chemokine ligand 5(CCL5),CC chemokine ligand 18(CCL18)and CC chemokine ligand 20(CCL20)]and vascular endothelial growth factor(VEGF)subtypes(VEGF-A,VEGF-B and VEGF-C)before and after treatment of two groups were compared.Result:The total effective rate of the observation group was significantly higher than that of control group,the difference was statistically significant(P<0.05).There was no significant difference in the various toxic and side effects rates between two groups(P>0.05).There were no significant differences in chemokine related indexes and VEGF subtypes between two groups before treatment(P>0.05);the chemokine related indexes and VEGF subtypes of the observation group at 2 cycles and 4 cycles of treatment were lower than those of the control group,the differences were statistically significant(P<0.05).Conclusion:The application effect of Epirubicin,Cyclophosphamide combined with Albumin-bound Paclitaxel in patients with breast cancer is better,its safety is worthy of affirmation,and it can significantly improve the chemokine related indexes and their their influence for angiogenesis.

关 键 词：白蛋白紫杉醇 表柔比星 环磷酰胺 乳腺癌 毒副反应 趋化因子 血管内皮生长因子亚型 

分 类 号：R737.9[医药卫生—肿瘤]